Patients in CheckMate 067 Demonstrate Durable Complete Responses

May 22, 2020

Georgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.

Pembrolizumab Plus Interleukin-12 Shows Activity in Metastatic Melanoma

May 08, 2020

"Combining pembrolizumab with Tavo electroporation improved responses for these patients who were predicted to have very poor responses to single-agent immune checkpoint inhibition."

Engineered Cellular Therapies Enter Treatment Landscape of Melanoma

May 04, 2020

In an interview with Targeted Oncology, Bruce L. Levine, PhD, discussed hot topics in the treatment landscape of melanoma, including the development of chimeric antigen receptor T and NK cells.

Combination Regimens Inspire Hope for the Treatment of Melanoma

May 04, 2020

In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.

Vemurafenib/Cobimetinib Plus Atezolizumab Combo Improves PFS in Advanced Melanoma

May 03, 2020

"Atezolizumab combined with vemurafenib and cobimetinib showed a statistically significant and clinically meaningful in progression-free survival via investigator assessment when compared with placebo plus vemurafenib and cobimetinib."

Weber Evaluates the Role of Neoadjuvant and Adjuvant Immunotherapy in Melanoma

April 22, 2020

In an interview with Targeted Oncology, Jeffrey S. Weber, MD, PhD, discussed the role of neoadjuvant and adjuvant therapy for the treatment of patients with melanoma. He also highlighted the role of immunotherapy, as well as other types of therapy, in this treatment landscape.

Evaluating Prognosis of Patients With Ocular Melanoma

April 17, 2020

Ragini Kudchadkar, MD, discusses the overall prognosis of patients with ocular melanoma.

Rarity of Uveal Melanoma Challenges Clinical Trial Enrollment

April 04, 2020

In an interview with Targeted Oncology, Richard D. Carvajal, MD, discussed the challenges of conducting clinical trials for the treatment of patients with uveal melanoma, as well as the excitement surrounding 2 potential therapies in this space.

Targeted Therapies Contribute to Significant Decline in Melanoma-Related Mortality

March 24, 2020

The mortality rate for cutaneous melanoma was significantly reduced between 2013 to 2016 as a result of new targeted therapies for metastatic disease, according to a recent report in the American Journal of Public Health. It is the largest death decline ever recorded for skin cancer.

Adjuvant Ipilimumab Dose Improves Survival Benefit for Resected High-Risk Melanoma

March 17, 2020

Adjuvant ipilimumab at a dose of 3 mg/kg demonstrated a survival benefit in patients with resected high-risk melanoma compared with high-dose interferon alfa-2b, according to the findings for a phase III E1609 clinical trial from the North American Intergroup.